Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Four New Biomarkers Identified for Cardiovascular Risk

By LabMedica International staff writers
Posted on 28 Jan 2015
A blood screening technology has uncovered four new biomarkers that improve the prediction of the risk for heart attack or stroke within the next 15 years. More...


The blood profiling technique may eventually help doctors to identify those people who would benefit the most from early treatment and high-throughput profiling of circulating metabolites may improve cardiovascular risk prediction over established risk factors.

An international team of scientists led by those at the University of Oulu (Finland) screened blood samples of 13,441 apparently healthy people from Finland and the UK for 68 biological markers. The health status of these volunteers was followed for over a decade. The team looked for measures in the blood that could reflect a heart attack or a stroke within the following years. Four biomarkers were indicative of future cardiovascular disease risk independently of known risk factors.

The team used a method based on Nuclear Magnetic Resonance (NMR) spectroscopy (Bruker, Billerica, MA, USA) which enables determination of over 200 biomarkers for body metabolism from a single blood sample. The technique is now being used for metabolic screening in large population studies and biobanks across Europe. All metabolites were measured in a single experimental setup, which allows for the simultaneous quantification of both routine lipids, total lipid concentrations of 14 lipoprotein subclasses, fatty acid composition such as monounsaturated (MUFA) and polyunsaturated fatty acids (PUFA), various glycolysis precursors, ketone bodies and amino acids in absolute concentration units. A subset of 679 serum samples from the study were additionally profiled with liquid-chromatography mass spectrometry (LC-MS) using the Metabolon platform (Durham, NC, USA).

The biomarkers for future cardiovascular disease were phenylalanine, a common amino acid, and the amount of monounsaturated fat in the blood; higher concentrations were linked with higher disease risk. These two biomarkers were as strong predictors of future heart disease as the measures of bad cholesterol or blood pressure. In addition, higher blood levels of both omega-3 and omega-6 fatty acids were linked with lower risk for cardiovascular disease. All these molecules are normally present in everyone’s blood, but it is the amount of these molecules that was shown to be reflecting the cardiovascular health.

Peter Würtz, PhD, the lead author, said, “These new biomarkers can help to better assess the complex molecular processes behind the development of cardiovascular disease. The improved prediction of cardiovascular risk also suggests cost savings in healthcare by advanced biomarker profiling. The low-cost blood screening technology opens a treasure trove to understand the molecular mechanisms of heart disease and other metabolic diseases.” The study was published on January 8, 2015, in the journal Circulation.

Related Links:

University of Oulu  
Bruker 
Metabolon



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.